Not yet recruitingPhase 1NCT07113496
RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
Studying Plasmablastic lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Principal Investigator
- Lei FanThe First Affiliated Hospital with Nanjing Medical University
- Intervention
- Allogeneic CAR-T(biological)
- Enrollment
- 27 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (1)
- The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07113496 on ClinicalTrials.govOther trials for Plasmablastic lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06781359Study on Plasmablastic Lymphoma PatientsFondazione Italiana Linfomi - ETS
- RECRUITINGPHASE2NCT04915248Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.Fondazione Italiana Linfomi - ETS
- RECRUITINGEARLY PHASE1NCT04139304A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic LymphomaAIDS Malignancy Consortium
- ACTIVE NOT RECRUITINGPHASE1NCT01961063Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin LymphomaCity of Hope Medical Center